Key result
Intravenous esmolol combined with ibutilide improved conversion of recent-onset atrial fibrillation to sinus rhythm compared to ibutilide alone (67% vs. 46%) with no polymorphic ventricular tachycardia.
Why the study?
Does the combination of intravenous esmolol and ibutilide improve conversion to sinus rhythm and reduce proarrhythmia compared to ibutilide alone in patients with recent-onset atrial fibrillation?
Population
88 patients with recent-onset atrial fibrillation with a rapid ventricular rate
Comparison
Intravenous esmolol and ibutilide combination vs Intravenous ibutilide alone
Design
Editorial, randomized
Authors
Loading...
Adding intravenous esmolol to ibutilide for pharmacological cardioversion of recent-onset atrial fibrillation improves conversion rates and significantly reduces the risk of torsade de pointes.
Does the combination of intravenous esmolol and ibutilide improve conversion to sinus rhythm and reduce proarrhythmia compared to ibutilide alone in patients with recent-onset atrial fibrillation?
Absolute Event Rate: 67% vs 46%
Adding intravenous esmolol to ibutilide for pharmacological cardioversion of recent-onset atrial fibrillation improves conversion rates and significantly reduces the risk of torsade de pointes.
Gopinathannair et al. (2008) conducted an editorial in Recent-onset atrial fibrillation with a rapid ventricular rate (n=88). Intravenous esmolol and ibutilide vs. Intravenous ibutilide alone was evaluated on Conversion to sinus rhythm. Intravenous esmolol combined with ibutilide improved conversion of recent-onset atrial fibrillation to sinus rhythm compared to ibutilide alone (67% vs. 46%) with no polymorphic ventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: